Results 231 to 240 of about 138,704 (292)

Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present)

Expert Opinion on Therapeutic Patents, 2020
Introduction: Histone deacetylase (HDAC) inhibitors play a crucial role in restoring the balance of acetylation and deacetylation of lysine residues of histones and non-histone proteins, which are applied to treat several diseases including cancer.
Chunlong Zhao, Hang Dong, Qifu Xu, Yingjie Zhang   +3 more
semanticscholar   +1 more source

Emerging role of histone deacetylase inhibitors as anti-breast-cancer agents.

Drug Discovery Today, 2019
Breast cancer (BC) remains the most frequently diagnosed cancer in women. A balance in the opposing actions of histone acetyltransferases (HATs) and histone deacetylases (HDACs) is necessary for epigenetic regulation of gene expression. Impairment in the
M. Ediriweera, K. Tennekoon, S. Samarakoon   +2 more
semanticscholar   +1 more source

Histone Deacetylase Inhibitors

2004
The base sequence of DNA provides the genetic code for proteins. The regulation of expression or suppression of gene transcription is largely determined by the structure of the chromatin--referred to as epigenetic gene regulation (Agalioti et al., 2002; Jenuwein and Allis, 2001; Richards and Elgin, 2002; Spotswood and Turner, 2002; Zhang and Reinberg ...
Paul A, Marks, Victoria M, Richon, Thomas, Miller, William Kevin, Kelly   +3 more
openaire   +6 more sources

The role of histone deacetylase inhibitors in metastatic breast cancer.

Breast, 2019
Histone deacetylase inhibitors (HDACi) are a relatively new class of drug that plays an important role in the epigenetic and non-epigenetic regulation in cancer, inducing death, apoptosis and cell cycle arrest in cancer cells. Although HDACi are approved
B. Zucchetti, A. Shimada, A. Katz, G. Curigliano   +3 more
semanticscholar   +1 more source

Histone Deacetylase Inhibitors in Cancer Therapy.

Current Topics in Medicinal Chemistry, 2019
Histone deacetylases (HDACs), as epigenetic modifiers, are essential for gene transcriptional activities. The alternation of HDACs expression, mutation and/or inappropriate recruitments has been discovered in a broad range of tumors contributing to the ...
Yijie Sun, Yanyi Sun, Saichao Yue, Yaohe Wang, Fanghui Lu   +4 more
semanticscholar   +1 more source

Histone deacetylase inhibitors in hepatocellular carcinoma: A therapeutic perspective.

Surgical oncology, 2018
Hepatocellular carcinoma (HCC) is a major contributor to the global cancer burden. Given the current limited options to treat advanced HCC, understanding the molecular basis of HCC carcinogenesis and pinpointing druggable targets will be important to ...
D. Tsilimigras, Ioannis Ntanasis-stathopoulos, D. Moris, E. Spartalis, T. Pawlik   +4 more
semanticscholar   +1 more source

Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy.

Journal of Medicinal Chemistry, 2018
Histone deacetylases (HDACs), encompassing at least 18 members, are promising targets for anticancer drug discovery and development. To date, five histone deacetylase inhibitors (HDACis) have been approved for cancer treatment, and numerous others are ...
Y. Luan, Jerry Li, Jean A. Bernatchez, Rongshi Li   +3 more
semanticscholar   +1 more source

Carbamazepine is an inhibitor of histone deacetylases

Life Sciences, 2005
Carbamazepine (CBZ) is a common antiepileptic drug (AED) that acts through multiple mechanisms including blockade and potentiation of cation channels and modulation of neurotransmitter levels. Whether it affects any component of the gene transcription machinery is unknown.
Andreas S, Beutler, SiDe, Li, Rebekka, Nicol, Martin J, Walsh   +3 more
openaire   +2 more sources

Selective Histone Deacetylase Inhibitors

Anti-Cancer Agents in Medicinal Chemistry, 2012
Histone deacetylases (HDACs) are a family of conserved metalloproteases which play a key role in the development of cancer. They can be divided into 18 subtypes according to their structural diversity. Histone deacetylase inhibitors are considered as potential anti-cancer agents and a lot of pan-HDAC inhibitors have entered clinical trials.
Huili, Pan, Jiangying, Cao, Wenfang, Xu
openaire   +2 more sources

Prospects: Histone deacetylase inhibitors

Journal of Cellular Biochemistry, 2005
AbstractHistone deacetylase (HDAC), inhibitors represent a new class of targeted anti‐cancer agents. Several of these compounds are in clinical trials with significant activity against a spectrum of both hematologic and solid tumors at doses that are well tolerated by the patients.
Milos, Dokmanovic, Paul A, Marks
openaire   +2 more sources